MedTrace Logo

Atorvastatin Treatment to Attenuate the Progression of Cardiovascular Disease in Hemodialysis Patients

NCT00481364 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 446

Last updated 2013-09-09

No results posted yet for this study

Summary

This prospective, randomized, controlled study aims to investigate the effects of atorvastatin treatment in hemodialysis patients concerning progression of coronary artery calcification, progression of carotid artery intima-media thickness, endothelial function, and inflammation.

Conditions

Interventions

DRUG

atorvastatin

atorvastatin 40 mg/day

DRUG

placebo

1 tb/day

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ercan OK

    lead OTHER

Principal Investigators

  • Ercan Ok, MD · Ege University, Division of Nephrology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00481364 on ClinicalTrials.gov